147 Results

People

  1. Horwitz
    Horwitz
  2. Salles
    Salles
  3. Usmani
    Usmani
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Perales
    Perales
  7. Batlevi
    Batlevi
  8. Moskowitz
    Moskowitz
  9. Palomba
    Palomba
  10. Shah
    Shah

Groups

  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)
  7. Weinberg Fellows (25)
  8. Biostatistics Service (23)
  9. Population Sciences Research Program (21)
  10. Survivorship Research (21)
  1. "overall response rate"
Formats
  1. Journal Article (114)
  2. Editorial (10)
  3. Review (8)
  4. Correspondence (6)
  5. Research Letter (6)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)

More Groups

People
  1. Andrew Zelenetz (9)
  2. Gilles Salles (9)
  3. Saad Usmani (9)
  4. Steven Horwitz (9)
  5. Anita Kumar (8)
  6. Miguel-Angel Perales (8)

More People

Years
  1. 2025 (23)
  2. 2024 (41)
  3. 2023 (32)
  4. 2022 (27)
  5. 2021 (17)
  6. 2020 (6)

More Years

Publications
  1. Leukemia and Lymphoma (13)
  2. Blood (10)
  3. Haematologica (9)
  4. ESMO Open (7)
  5. Leukemia (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Nature Publishing Group (19)
  3. American Society of Hematology (16)
  4. Taylor & Francis Group (13)
  5. Oxford University Press (11)
  6. Ferrata Storti Foundation (9)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effectiveness and safety of combined treatment with herbal medicines and palliative chemotherapy for advanced gastric cancer: A systematic review, and meta-analysis
    Review

    Kim, D. H.; Kim, S. D.; Jun, H. J.; Kwag, E. B.; Shin, S. W.; Yoo, H. S.; Park, S. J.
    Integrative Medicine Research (2025)

    Fulltext@MSK | Save
  • A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas
    Journal Article

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhailova, N.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; Emig, M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • The role of radiotherapy in lymphoma patients undergoing CAR T therapy: Past, present, and future
    Review

    Wallington, D. G.; Imber, B. S.; Scordo, M.; Robinson, T. J.
    Seminars in Radiation Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
    Journal Article

    André, F.; Cortés, J.; Curigliano, G.; Modi, S.; Li, W.; Park, Y. H.; Chung, W. P.; Kim, S. B.; Yamashita, T.; Pedrini, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: The FORT-2 phase 1b nonrandomized clinical trial
    Journal Article

    Sweis, R. F.; Gajate, P.; Morales-Barrera, R.; Lee, J. L.; Necchi, A.; De Braud, F.; Penel, N.; Grünwald, V.; Maruzzo, M.; Meran, J.; more...
    JAMA Oncology (2024)

    Fulltext@MSK | Save
  • Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma
    Journal Article

    Benjamini, O.; Fried, S.; Shouval, R.; Flynn, J. R.; Beyar-Katz, O.; Leslie, L. A.; Zuckerman, T.; Yerushalmi, R.; Shem-Tov, N.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Response to: Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: The real challenge?
    Correspondence

    Vogel, A.; Zhen, H.; Veronese, M. L.; Abou-Alfa, G. K.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma
    Journal Article

    Lorenc, R.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Saldia, A.; Luna De Abia, A.; De Lapuerta, M. C.; Tomas, A. A.; Cassanello, G.; Leslie, L. A.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save